Heartworm Disease in Dogs: Welfare and Prevention

Key Welfare Considerations

• Dirofilaria immitis larvae are transmitted by mosquitoes and develop into adult worms residing in the pulmonary arteries.
• Adult worms cause progressive pulmonary hypertension, right-sided heart failure, and severe welfare deterioration.
• Clinical signs develop gradually — exercise intolerance, coughing, weight loss, and eventual cardiac failure.
• Caval syndrome from massive worm burden causes acute life-threatening welfare emergency requiring surgical extraction.
• Heartworm is endemic in Southern USA, Mediterranean Europe, and increasingly in other temperate regions.
• Annual heartworm antigen testing before prophylaxis prescription enables early detection for welfare.
• Melarsomine dihydrochloride treatment requires strict exercise restriction — welfare-critical compliance required.
• Exercise restriction during treatment is mandatory — physical activity risks fatal pulmonary thromboembolism.
• Pre-treatment corticosteroids reduce inflammatory welfare responses to dying worms.
• Microfilaremia treatment with macrocyclic lactones after adulticidal therapy eliminates circulating larvae.
• Monthly macrocyclic lactone prophylaxis (ivermectin, milbemycin) is 99%+ effective welfare prevention.
• Collie breeds have MDR1 gene mutation causing ivermectin toxicity — welfare-appropriate dose selection required.
• Heartworm prophylaxis combined with flea, tick, and intestinal parasite coverage provides broad welfare protection.
• Climate change is expanding mosquito ranges, increasing heartworm welfare risk in previously unaffected regions.
• Prevention is dramatically cheaper and kinder than treatment — heartworm prophylaxis is a welfare priority.